Disc Medicine, 8-K (7.01, 8.01, 9.01): Regulation FD disclosure

Disc Medicine reported that bitopertin met all primary and secondary endpoints in its 183-patient Phase 3 APOLLO trial for EPP, including a 41.4% PPIX reduction and 12.2 additional monthly hours in light without pain versus placebo, and plans an NDA resubmission by end-2026.